US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OS Therapies

1.36

+0.09007.09%

Post-market: 1.390.0300+2.21%19:18 EST

Volume:630.57K

Turnover:865.30K

Market Cap:47.89M

PE:-1.74

High:1.44

Open:1.30

Low:1.30

Close:1.27

52wk High:2.98

52wk Low:1.12

Shares:35.21M

Float Shares:22.09M

Volume Ratio:1.18

T/O Rate:2.85%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7796

EPS(LYR):-0.8795

ROE:-914.04%

ROA:-225.11%

PB:13.17

PE(LYR):-1.55

Loading ...

Overview Company News Filings

OS Therapies Is Maintained at Buy by D. Boral Capital

Os Therapies: Has Initiated Submission of a Bla to U.S. FDA for Ost-Her2

THOMSON REUTERS

OS Therapies Initiates FDA Biologics License Application Review for OST-HER2 in Metastatic Osteosarcoma

OS Therapies Reports Positive Phase 2b Biomarker Data for OST-HER2 in Osteosarcoma Trial

OS Therapies Subsidiary OS Animal Health Files for IPO

OS Therapies Raises $7.53 Million Through Warrant Exercise Inducement

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Prepares FDA Submission for OST-HER2 in Metastatic Osteosarcoma

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Advances OST-HER2 Osteosarcoma Trial After Positive FDA Meeting

OS Therapies Unveils Cancer Immunotherapy Pipeline and Market Strategy in New Presentation

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Is Maintained at Buy by D. Boral Capital

BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee

Os Therapies: Scheduled Type C Meeting With United States Food & Drug Administration on December 11, 2025 for Ost-Her2

THOMSON REUTERS

Os Therapies: Scheduled Pre-Marketing Authorisation Application Meeting With UK's Mhra on Dec 8 for Ost-Her2

THOMSON REUTERS

Os Therapies: U.S. FDA Granted a Waiver of Application Fee for Its Bla Filing for Ost-Her2

THOMSON REUTERS

OS Therapies Inc. reports 2-year overall survival rate of 75% for OST-HER2 in Phase 2b trial

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Is Maintained at Buy by Lake Street

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OSTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OSTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","market":"US","secType":"STK","nameCN":"OS Therapies","latestPrice":1.36,"timestamp":1770411600000,"preClose":1.27,"halted":0,"volume":630567,"hourTrading":{"tag":"盘后","latestPrice":1.39,"preClose":1.36,"latestTime":"19:18 EST","volume":13362,"amount":18521.31,"timestamp":1770423496708,"change":0.03,"changeRate":0.022059,"amplitude":0.036765},"delay":0,"changeRate":0.07086614173228353,"floatShares":22089100,"shares":35214352,"eps":-0.779604,"marketStatus":"Market Closed","change":0.09,"latestTime":"02-06 16:00:00 EST","open":1.3,"high":1.435,"low":1.295,"amount":865303.5739509,"amplitude":0.110236,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.779604,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1719460800000,"exchange":"AMEX","adjPreClose":1.27,"preHourTrading":{"tag":"盘前","latestPrice":1.3099,"preClose":1.27,"latestTime":"09:20 EST","volume":2363,"amount":3087.7814866999997,"timestamp":1770387625633,"change":0.0399,"changeRate":0.031417,"amplitude":0.039213},"postHourTrading":{"tag":"盘后","latestPrice":1.39,"preClose":1.36,"latestTime":"19:18 EST","volume":13362,"amount":18521.31,"timestamp":1770423496708,"change":0.03,"changeRate":0.022059,"amplitude":0.036765},"volumeRatio":1.1789730160880612},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","floatShares":22089100,"roa":"-225.11%","roe":"-914.04%","lyrEps":-0.879526,"volumeRatio":1.1789730160880612,"shares":35214352,"dividePrice":0,"high":1.435,"amplitude":0.110236,"preClose":1.27,"low":1.295,"week52Low":1.12,"pbRate":"13.17","week52High":2.98,"institutionHeld":0,"latestPrice":1.36,"eps":-0.779604,"divideRate":0,"volume":630567,"delay":0,"ttmEps":-0.779604,"open":1.3,"prevYearClose":1.4,"prevWeekClose":1.36,"prevMonthClose":1.36,"prevQuarterClose":1.4,"fiveDayClose":1.36,"twentyDayClose":1.54,"sixtyDayClose":1.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OSTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OSTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OSTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1743570000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OSTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OSTX","date":"2026-02-06","current":-1.744475,"percent":1,"low":-14.897496,"twenty":-9.413543,"median":-4.875301,"eighty":-3.908145,"high":-2.445943,"avg":-6.215291,"sd":3.186533,"marketCap":44722227},"quantilePoints":[{"date":"2024-06-14","current":-13.217965,"twenty":-13.216533,"median":-13.214385,"eighty":-13.212238,"marketCap":102988885},{"date":"2024-06-21","current":-10.574372,"twenty":-13.217965,"median":-13.214385,"eighty":-12.156232,"marketCap":82391108},{"date":"2024-06-28","current":-13.217965,"twenty":-13.217965,"median":-13.217965,"eighty":-13.210806,"marketCap":102988885},{"date":"2024-08-02","current":-6.458845,"twenty":-13.217965,"median":-13.217965,"eighty":-11.101659,"marketCap":50324634},{"date":"2024-08-09","current":-8.117559,"twenty":-13.217965,"median":-10.433676,"eighty":-8.215548,"marketCap":63248641},{"date":"2024-08-16","current":-10.993719,"twenty":-13.216533,"median":-10.29298,"eighty":-8.15204,"marketCap":70975778},{"date":"2024-08-23","current":-13.004275,"twenty":-13.182439,"median":-10.833368,"eighty":-8.309008,"marketCap":83955991},{"date":"2024-08-30","current":-11.710317,"twenty":-13.188909,"median":-11.710317,"eighty":-8.610078,"marketCap":75602161},{"date":"2024-09-06","current":-12.939577,"twenty":-13.217965,"median":-12.391225,"eighty":-8.620371,"marketCap":83538300},{"date":"2024-09-13","current":-11.32213,"twenty":-13.217965,"median":-12.261039,"eighty":-9.289415,"marketCap":73096012},{"date":"2024-09-20","current":-11.483875,"twenty":-13.217965,"median":-11.710317,"eighty":-10.29298,"marketCap":74140241},{"date":"2024-09-27","current":-9.575287,"twenty":-13.210806,"median":-11.435351,"eighty":-9.575287,"marketCap":61818342},{"date":"2024-10-04","current":-9.727327,"twenty":-13.101322,"median":-11.354479,"eighty":-9.316172,"marketCap":62799917},{"date":"2024-10-11","current":-9.931126,"twenty":-13.068973,"median":-11.192735,"eighty":-9.413543,"marketCap":64115645},{"date":"2024-10-18","current":-9.769381,"twenty":-13.068973,"median":-10.859351,"eighty":-9.542938,"marketCap":63071416},{"date":"2024-10-25","current":-9.413543,"twenty":-13.004275,"median":-10.610453,"eighty":-9.542938,"marketCap":60774113},{"date":"2024-10-31","current":-8.782738,"twenty":-12.952517,"median":-10.592413,"eighty":-9.394069,"marketCap":56701621},{"date":"2024-11-08","current":-9.085848,"twenty":-12.836061,"median":-10.29298,"eighty":-9.218608,"marketCap":58658505},{"date":"2024-11-15","current":-7.116768,"twenty":-12.603148,"median":-10.141393,"eighty":-8.950952,"marketCap":45946065},{"date":"2024-11-22","current":-5.272053,"twenty":-12.423258,"median":-9.769381,"eighty":-8.605027,"marketCap":38782655},{"date":"2024-11-29","current":-6.178419,"twenty":-12.235002,"median":-9.759676,"eighty":-8.507772,"marketCap":45450128},{"date":"2024-12-06","current":-5.370028,"twenty":-11.917351,"median":-9.716005,"eighty":-8.143742,"marketCap":39503383},{"date":"2024-12-13","current":-12.876517,"twenty":-11.917351,"median":-9.704683,"eighty":-7.804035,"marketCap":94723165},{"date":"2024-12-20","current":-11.288606,"twenty":-11.937313,"median":-9.73218,"eighty":-8.125896,"marketCap":83042057},{"date":"2024-12-27","current":-14.738704,"twenty":-12.001827,"median":-9.761941,"eighty":-8.139646,"marketCap":108421919},{"date":"2025-01-03","current":-12.068126,"twenty":-12.384347,"median":-9.850254,"eighty":-8.168424,"marketCap":88776420},{"date":"2025-01-10","current":-14.782011,"twenty":-12.810182,"median":-10.086184,"eighty":-8.234384,"marketCap":108740495},{"date":"2025-01-17","current":-11.8949,"twenty":-12.876517,"median":-10.189917,"eighty":-8.475423,"marketCap":87502117},{"date":"2025-01-24","current":-8.430366,"twenty":-12.823449,"median":-10.125219,"eighty":-8.466412,"marketCap":62016063},{"date":"2025-01-31","current":-5.629868,"twenty":-12.632281,"median":-9.850254,"eighty":-8.128675,"marketCap":41414837},{"date":"2025-02-07","current":-5.600996,"twenty":-12.558673,"median":-9.759676,"eighty":-7.471942,"marketCap":41202453},{"date":"2025-02-14","current":-5.745352,"twenty":-12.423258,"median":-9.716005,"eighty":-6.985183,"marketCap":42264372},{"date":"2025-02-21","current":-5.456641,"twenty":-12.370592,"median":-9.688508,"eighty":-6.36129,"marketCap":40140534},{"date":"2025-02-28","current":-4.734863,"twenty":-12.322192,"median":-9.575287,"eighty":-6.039722,"marketCap":34830939},{"date":"2025-03-07","current":-4.850347,"twenty":-12.19815,"median":-9.413543,"eighty":-5.818713,"marketCap":35680475},{"date":"2025-03-14","current":-4.619378,"twenty":-12.093217,"median":-9.316172,"eighty":-5.658739,"marketCap":33981404},{"date":"2025-03-21","current":-4.590507,"twenty":-12.033481,"median":-9.267973,"eighty":-5.589448,"marketCap":33769021},{"date":"2025-03-28","current":-4.677121,"twenty":-11.941094,"median":-9.085848,"eighty":-5.445093,"marketCap":34406172},{"date":"2025-04-04","current":-3.682014,"twenty":-11.842932,"median":-9.000397,"eighty":-5.346931,"marketCap":32707102},{"date":"2025-04-11","current":-2.731469,"twenty":-11.788323,"median":-8.747948,"eighty":-5.012916,"marketCap":24263468},{"date":"2025-04-17","current":-3.828934,"twenty":-11.749136,"median":-8.669517,"eighty":-4.901959,"marketCap":34012183},{"date":"2025-04-25","current":-3.926486,"twenty":-11.61974,"median":-8.601309,"eighty":-4.833024,"marketCap":34878735},{"date":"2025-05-02","current":-4.706906,"twenty":-11.475058,"median":-8.516979,"eighty":-4.792605,"marketCap":41811155},{"date":"2025-05-09","current":-4.804459,"twenty":-11.45771,"median":-8.491597,"eighty":-4.792605,"marketCap":42677707},{"date":"2025-05-16","current":-4.048427,"twenty":-11.438586,"median":-8.234384,"eighty":-4.718089,"marketCap":35961926},{"date":"2025-05-23","current":-2.933033,"twenty":-11.406237,"median":-8.124506,"eighty":-4.677121,"marketCap":33145630},{"date":"2025-05-30","current":-3.928425,"twenty":-11.380358,"median":-7.63641,"eighty":-4.64825,"marketCap":44394361},{"date":"2025-06-06","current":-4.052742,"twenty":-11.348009,"median":-7.333748,"eighty":-4.596281,"marketCap":45799246},{"date":"2025-06-13","current":-4.574874,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"marketCap":51699762},{"date":"2025-06-20","current":-4.525147,"twenty":-11.288606,"median":-6.448552,"eighty":-4.525147,"marketCap":51137808},{"date":"2025-06-27","current":-4.500284,"twenty":-11.257432,"median":-6.245836,"eighty":-4.450557,"marketCap":50856831},{"date":"2025-07-03","current":-4.804944,"twenty":-11.153916,"median":-6.178419,"eighty":-4.480042,"marketCap":54299732},{"date":"2025-07-11","current":-4.384839,"twenty":-11.071717,"median":-6.001438,"eighty":-4.444649,"marketCap":49552214},{"date":"2025-07-18","current":-4.411096,"twenty":-11.057637,"median":-5.848373,"eighty":-4.413618,"marketCap":49848934},{"date":"2025-07-25","current":-5.118748,"twenty":-11.006503,"median":-5.726085,"eighty":-4.413618,"marketCap":57845975},{"date":"2025-08-01","current":-5.266689,"twenty":-10.886225,"median":-5.658739,"eighty":-4.423405,"marketCap":59517824},{"date":"2025-08-08","current":-5.177924,"twenty":-10.817778,"median":-5.632611,"eighty":-4.43502,"marketCap":58514715},{"date":"2025-08-15","current":-6.36145,"twenty":-10.649839,"median":-5.600996,"eighty":-4.43838,"marketCap":71889507},{"date":"2025-08-22","current":-5.360009,"twenty":-10.610453,"median":-5.567348,"eighty":-4.444649,"marketCap":76540639},{"date":"2025-08-29","current":-5.047341,"twenty":-10.610453,"median":-5.538676,"eighty":-4.449676,"marketCap":72075768},{"date":"2025-09-05","current":-4.667674,"twenty":-10.601601,"median":-5.456641,"eighty":-4.458388,"marketCap":66654139},{"date":"2025-09-12","current":-5.119065,"twenty":-10.582903,"median":-5.4212,"eighty":-4.477891,"marketCap":73099984},{"date":"2025-09-19","current":-4.897461,"twenty":-10.460155,"median":-5.370028,"eighty":-4.495136,"marketCap":69935483},{"date":"2025-09-26","current":-4.675856,"twenty":-10.329392,"median":-5.362697,"eighty":-4.515202,"marketCap":66770981},{"date":"2025-10-03","current":-4.409931,"twenty":-10.231142,"median":-5.325865,"eighty":-4.459866,"marketCap":62973579},{"date":"2025-10-10","current":-4.520733,"twenty":-10.170508,"median":-5.292169,"eighty":-4.471291,"marketCap":64555830},{"date":"2025-10-17","current":-4.099684,"twenty":-10.138159,"median":-5.266689,"eighty":-4.443146,"marketCap":58543277},{"date":"2025-10-24","current":-4.250282,"twenty":-10.078376,"median":-5.177924,"eighty":-4.421116,"marketCap":60693806},{"date":"2025-10-31","current":-4.156353,"twenty":-9.977535,"median":-5.177924,"eighty":-4.412988,"marketCap":59352507},{"date":"2025-11-07","current":-4.273765,"twenty":-9.834079,"median":-5.118748,"eighty":-4.402429,"marketCap":61029131},{"date":"2025-11-14","current":-4.273765,"twenty":-9.766275,"median":-5.104544,"eighty":-4.391176,"marketCap":61029131},{"date":"2025-11-21","current":-2.971008,"twenty":-9.761488,"median":-5.059977,"eighty":-4.38129,"marketCap":54322633},{"date":"2025-11-28","current":-3.447432,"twenty":-9.750618,"median":-5.0362,"eighty":-4.358965,"marketCap":63033690},{"date":"2025-12-05","current":-3.50521,"twenty":-9.73315,"median":-4.994703,"eighty":-4.321289,"marketCap":64090120},{"date":"2025-12-12","current":-3.909657,"twenty":-9.718269,"median":-4.969558,"eighty":-4.300776,"marketCap":71485134},{"date":"2025-12-19","current":-3.081503,"twenty":-9.704683,"median":-4.950787,"eighty":-4.273765,"marketCap":56342963},{"date":"2025-12-26","current":-2.927428,"twenty":-9.698213,"median":-4.936226,"eighty":-4.231496,"marketCap":53525815},{"date":"2026-01-02","current":-2.696315,"twenty":-9.672334,"median":-4.919621,"eighty":-4.226786,"marketCap":49300092},{"date":"2026-01-09","current":-2.965947,"twenty":-9.672334,"median":-4.910716,"eighty":-4.157441,"marketCap":54230102},{"date":"2026-01-16","current":-2.811872,"twenty":-9.575287,"median":-4.897871,"eighty":-4.145979,"marketCap":51412953},{"date":"2026-01-23","current":-2.831131,"twenty":-9.549408,"median":-4.897461,"eighty":-4.087363,"marketCap":51765097},{"date":"2026-01-30","current":-2.657797,"twenty":-9.439422,"median":-4.891008,"eighty":-3.973179,"marketCap":48595805},{"date":"2026-02-06","current":-2.445943,"twenty":-9.413543,"median":-4.875301,"eighty":-3.908145,"marketCap":44722227}],"updateTime":1770563787013},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OSTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609731377","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2609731377","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609731377?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:36","pubTimestamp":1770294960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 05, 2026 07:36 ET (12:36 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2608754868","title":"Os Therapies:  Has Initiated Submission of a Bla to U.S. FDA for Ost-Her2","url":"https://stock-news.laohu8.com/highlight/detail?id=2608754868","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608754868?lang=en_us&edition=fundamental","pubTime":"2026-02-02 19:09","pubTimestamp":1770030582,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YY0XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2608684878","title":"OS Therapies Initiates FDA Biologics License Application Review for OST-HER2 in Metastatic Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2608684878","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608684878?lang=en_us&edition=fundamental","pubTime":"2026-02-02 19:01","pubTimestamp":1770030075,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has initiated the submission of a Biologics License Application  to the U.S. Food & Drug Administration  for OST-HER2, a listeria-based immunotherapy aimed at preventing or delaying recurrence of fully resected, pulmonary metastatic osteosarcoma. The company has submitted the Non-Clinical and Chemistry, Manufacturing, and Controls  modules and requested a Rolling Review from the FDA. Following a recent Type C Meeting with the FDA, OS Therapies expects to participate in a Type D Meeting in March 2026 to review Comparative Oncology biomarker data from both human and canine trials. The final clinical module of the BLA is expected to be submitted by the end of March 2026. Additionally, OS Therapies has updated its Regenerative Medicine Advanced Therapy  designation request with new biomarker data. OST-HER2 has received Orphan Disease Designation, Fast Track Designation, and Rare Pediatric Disease Designation from the FDA, and the company remains on track for potential app","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL5WDnZh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2603047196","title":"OS Therapies Reports Positive Phase 2b Biomarker Data for OST-HER2 in Osteosarcoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2603047196","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603047196?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:01","pubTimestamp":1768478488,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. announced positive biomarker data from its Phase 2b clinical trial of OST-HER2, aimed at preventing or delaying recurrent, fully resected, pulmonary metastatic osteosarcoma. The results, which have already been presented, indicate that activation of immune blood biomarkers in the interferon gamma pathway distinguished long-term survivors  from short-term survivors . The company utilized a pre-specified pathway analysis strategy based on data from a 118-patient canine metastatic osteosarcoma study published in February 2025. OS Therapies is preparing its Biologics License Application  and Marketing Authorisation Application submissions, targeting regulatory approval for OST-HER2 in the UK by the end of the second quarter of 2026, in the US by the end of the third quarter of 2026, and in Europe by year end 2026. OST-HER2 has received FDA Orphan Disease Designation, Fast Track Designation from FDA and EMA, and Rare Pediatric Disease Designation from the FDA.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL8hszdY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2603613886","title":"OS Therapies Subsidiary OS Animal Health Files for IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2603613886","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603613886?lang=en_us&edition=fundamental","pubTime":"2026-01-14 20:01","pubTimestamp":1768392110,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. announced that its wholly-owned subsidiary, OS Animal Health Corp , has filed a Form S-1 with the SEC in preparation for an Initial Public Offering . OSAH intends to list on either the NYSE American or Nasdaq Capital Markets national stock exchange in the first half of 2026. OS Therapies shareholders are expected to receive one share of OSAH for every ten shares of OS Therapies owned as of a record date to be determined in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on January 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL41R4F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014005.SGD","SG9999014013.SGD","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","OSTX","LU2210150020.SGD","BK4139","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","BK4588","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2602510329","title":"OS Therapies Raises $7.53 Million Through Warrant Exercise Inducement","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510329","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510329?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:03","pubTimestamp":1768223039,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has announced the successful completion of a warrant exercise inducement and exchange offer with nine accredited investors, raising $7.53 million in gross proceeds. All nine investors holding existing warrants agreed to exercise or pre-fund their warrants for cash. The funds will extend the company’s capital runway into 2027 and will be used to support regulatory filings and commercial preparations for OST-HER2 in metastatic osteosarcoma, as well as preparations for the proposed spinoff of its subsidiary, OS Animal Health.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on January 12, 2026, and is solely responsible for the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLVl0jR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2601388490","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601388490","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601388490?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:39","pubTimestamp":1767620340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 08:39 ET (13:39 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2601889635","title":"OS Therapies Prepares FDA Submission for OST-HER2 in Metastatic Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2601889635","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601889635?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:41","pubTimestamp":1767616881,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. announced it is finalizing preparations for a U.S. FDA Biologics License Application  submission for its lead candidate, OST-HER2, targeting the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. The company expects to submit the BLA under the FDA's Accelerated Approval Program by the end of January 2026. Additionally, OS Therapies plans to submit Marketing Authorisation Applications  for conditional approval of OST-HER2 in the U.K. and Europe by the end of February and March 2026, respectively. The company anticipates multiple meetings with the U.S. FDA, U.K. MHRA, and Europe's EMA in the first half of 2026 as part of the regulatory review process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL39mfrw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2591641614","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2591641614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591641614?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:29","pubTimestamp":1765805340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 08:29 ET (13:29 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2591648672","title":"OS Therapies Advances OST-HER2 Osteosarcoma Trial After Positive FDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648672","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591648672?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:01","pubTimestamp":1765796489,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. announced progress in its research and development of OST-HER2, a listeria-based cancer immunotherapy aimed at preventing or delaying recurrent, fully resected, pulmonary metastatic osteosarcoma. Following a successful Type C meeting with the FDA, the company reported that data from their ongoing Phase 2b clinical trial, including immune activation biomarker results, may support a Biologics License Application  under the FDA's Accelerated Approval Program. The FDA confirmed that single-arm studies in rare diseases could be considered for this pathway and suggested a confirmatory, randomized study in additional osteosarcoma settings. OS Therapies plans to present new biomarker data from both human and canine studies to the FDA in a forthcoming meeting, with the intent to file BLA documents by the end of January 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLMcdLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2590535898","title":"OS Therapies Unveils Cancer Immunotherapy Pipeline and Market Strategy in New Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2590535898","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590535898?lang=en_us&edition=fundamental","pubTime":"2025-12-10 22:57","pubTimestamp":1765378623,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has published a corporate presentation highlighting its clinical-stage pipeline and financial summary. The company reports over $300 million invested in its listeria immunotherapy platform, acquired from Advaxis/Ayala in April 2025. The lead program, OST-HER2, targets osteosarcoma and has potential follow-on applications in breast cancer and other solid tumors. The total addressable market for these assets is estimated at $258 billion. The company is targeting accelerated approval for OST-HER2 in human osteosarcoma between April and September 2026, with a projected Priority Review Voucher sale of approximately $160 million. The clinical pipeline also includes candidates for HPV cancers, non-small cell lung cancer, glioblastoma, breast cancer, and prostate cancer. Current financials show a market cap of $60 million, cash holdings of approximately $4 million, and a monthly cash burn of about $300,000. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLWhznZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX","ADXS"],"gpt_icon":0},{"id":"2590553342","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2590553342","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590553342?lang=en_us&edition=fundamental","pubTime":"2025-12-09 22:20","pubTimestamp":1765290000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 09:20 ET (14:20 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2589812399","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2589812399","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589812399?lang=en_us&edition=fundamental","pubTime":"2025-12-06 03:10","pubTimestamp":1764961800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 05, 2025 14:10 ET (19:10 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2589979098","title":"BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2589979098","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589979098?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:06","pubTimestamp":1764939961,"startTime":"0","endTime":"0","summary":"BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee Dec 5  - OS Therapies Inc OSTX.A:OS THERAPIES: U.S. FDA GRANTED A WAIVER OF APPLICATION FEE FOR ITS BLA FILING FOR OST-HER2OS THERAPIES: SCHEDULED PRE-MARKETING AUTHORISATION APPLICATION MEETING WITH UK'S MHRA ON DEC 8 FOR OST-HER2OS THERAPIES: SCHEDULED TYPE C MEETING WITH UNITED STATES FOOD & DRUG ADMINISTRATION ON DECEMBER 11, 2025 FOR OST-HER2Source text: [ID:]Further company coverage: OSTX.A ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2589897970","title":"Os Therapies: Scheduled Type C Meeting With United States Food & Drug Administration on December 11, 2025 for Ost-Her2","url":"https://stock-news.laohu8.com/highlight/detail?id=2589897970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589897970?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:03","pubTimestamp":1764939828,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2589897679","title":"Os Therapies: Scheduled Pre-Marketing Authorisation Application Meeting With UK's Mhra on Dec 8 for Ost-Her2","url":"https://stock-news.laohu8.com/highlight/detail?id=2589897679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589897679?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:03","pubTimestamp":1764939828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2589677897","title":"Os Therapies: U.S. FDA Granted a Waiver of Application Fee for Its Bla Filing for Ost-Her2","url":"https://stock-news.laohu8.com/highlight/detail?id=2589677897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589677897?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:03","pubTimestamp":1764939828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2585836126","title":"OS Therapies Inc. reports 2-year overall survival rate of 75% for OST-HER2 in Phase 2b trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2585836126","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585836126?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:16","pubTimestamp":1763759777,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. reported a net loss of $6.9 million for the quarter, ending with approximately $1.9 million in cash. After the quarter, the company raised $7.8 million from warrant proceeds and has an at-the-market facility in place, extending its cash runway into late 2026. Key business developments included progress toward regulatory filings for OST-HER2, with a UK pre-MAA in December and an FDA Type C meeting on December 11, targeting filings in January 2026. The company also announced plans to spin off OS Animal Health in the first half of 2026, with current shareholders expected to receive direct equity in the new entity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDLGbkBS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OS Therapies Inc. reports 2-year overall survival rate of 75% for OST-HER2 in Phase 2b trial","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2585367145","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2585367145","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585367145?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:22","pubTimestamp":1763731320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 08:22 ET (13:22 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2584577159","title":"OS Therapies Is Maintained at Buy by Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2584577159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584577159?lang=en_us&edition=fundamental","pubTime":"2025-11-19 02:19","pubTimestamp":1763489940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 13:19 ET (18:19 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}]}}